Orchestra Bio exceeds BACKBEAT trial enrollment target
Orchestra Bio exceeded its BACKBEAT trial enrollment target by randomizing 330 patients, surpassing the initial goal of 316 patients.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Orchestra BioMed exceeds full enrollment target in BACKBEAT trial
Orchestra BioMed said the BACKBEAT Global pivotal trial of AVIM therapy has exceeded its full enrollment target.